FrameworkLTC's fully integrated and scalable platform automates all manual tasks, allowing LTC pharmacies to focus on what is most important: improving patient lives. Automation replaces manual tasks and allows you to expand your business while maximising margins. Delivering services that meet the needs of each facility will strengthen your partner relationships. Our facility-centric software allows you to provide concierge-level service, catering to every patient, wing, and facility. Allow facilities to print bills, check order statuses, and process returns according to your pre-defined rules. Your facilities will appreciate your reports. Automate refill and reorder prescriptions so they don't get lost on the production floor.
Learn more
JDisc Discovery is a powerful IT asset management and network discovery tool, designed to provide organizations with clear, real-time insights into their entire IT environment. By automatically scanning the network, it identifies and catalogs devices, from physical servers and workstations to virtual machines and network appliances, giving users a detailed inventory of their assets. The tool captures essential data such as hardware specifications, installed software, system configurations, and interdependencies among devices.
A key advantage of JDisc Discovery is its agentless architecture. Rather than requiring installation on each device, it uses multiple protocols (like SNMP, SSH, WMI) to gather information, ensuring quick deployment and compatibility across various operating systems, including Windows, Linux, and Unix. This makes it ideal for diverse and dynamic IT ecosystems, enabling efficient and non-intrusive data collection.
Learn more
Atomwise
Our innovative AI engine is revolutionizing the drug discovery process, enabling the creation of superior medications at an accelerated pace. The breakthroughs we achieve contribute to the development of medicines more efficiently and effectively. Our portfolio of AI-driven discoveries encompasses entirely owned and collaboratively developed pipeline assets, supported by leading investors in the industry. Atomwise has engineered a cutting-edge machine-learning discovery platform that merges the capabilities of convolutional neural networks with extensive chemical libraries to identify new small-molecule treatments. The key to transforming drug discovery through AI lies in our talented team. We are committed to enhancing our AI platform and leveraging it to revolutionize the discovery of small molecule drugs. It is essential that we confront the most daunting and seemingly insurmountable targets, streamlining the entire drug discovery process to provide developers with increased opportunities for success. Enhanced computational efficiency allows us to screen trillions of compounds virtually, significantly boosting the chances of finding viable solutions. Our impressive model accuracy has successfully addressed the persistent issue of false positives, underscoring the reliability of our approach. Ultimately, our dedication to innovation and excellence sets us apart in the quest for breakthrough therapies.
Learn more
BenevolentAI
BenevolentAI is a pioneering platform that leverages artificial intelligence and scientific technology to enhance drug discovery processes, specifically targeting complex diseases by efficiently processing and interpreting extensive biomedical data to yield actionable insights more swiftly than conventional approaches. By utilizing its unique Benevolent Platform, the company seamlessly integrates both structured and unstructured biomedical information—spanning literature, genomics, clinical data, and multi-omics—into a detailed knowledge graph. This robust framework empowers researchers to analyze biological systems, formulate testable hypotheses, identify new drug targets, and create potential drug candidates with increased confidence and reduced failure rates, ultimately transforming the landscape of medicine development. With its innovative approach, BenevolentAI stands at the forefront of a new era in the pharmaceutical industry.
Learn more